Future Health Lab
Alfred-Adler-Straße 1, Vienna, Austria
Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used for the diagnosis (i.e., staging and restaging) and treatment of patients with prostate cancer. Radionuclide PSMA therapy is a useful new treatment […]
What sessions can you expect? The course will last approximately 3,25 hours. Learning Objectives Target Audience Faculty Registration Details Event Overview
Radionuclide Theranostics is evolving and expanding in the field of nuclear medicine in various clinical settings. Its principle is based on therapeutic interventions after imaging to confirm the presence of […]
While PET imaging with radionuclides such as F18 and Ga68 have proven to provide high quality diagnostic imaging, imaging with other radionuclides can be more challenging. Zr-89 is one such […]